58 min
Immunotherapy for MS. A guide to efficacy and choice with Prof. Tjalf Ziemssen MS-Perspektive - The Multiple Sclerosis Podcast
-
- Saúde e fitness
Choosing the right immunotherapy for each individual patient is a complex process. Prof. Ziemssen explains what needs to be considered.
You can read the full transcript of the interview here: https://ms-perspektive.com/58-immunotherapy
Today’s interview on immunotherapy for MS marks the start of the series on disease-modifying therapies. It is also episode 250 for the German podcast and I translated it into English. I have once again invited Prof. Dr. Tjalf Ziemssen, who is one of the most committed MS experts and, among other things, initiated the Multiple Sclerosis Management Master’s program in German and English, which I myself have been attending since August 2022. Thanks to this very well-founded study program, I have gained enough expertise to be able to pass on my knowledge of the therapies to you.
Prof. Ziemssen answers important questions about the procedure, the selection and why it is so important to appreciate it when you see nothing in MS, when you manage to achieve disease remission. We also talk about why it is sometimes more important to move quickly into preventative therapy rather than focusing on rehabilitation and relapse treatment first. A brief detour leads to generics and biosimilars, which are increasingly playing a role in the drug landscape. We talk about how important it is to prevent MS activities as early as possible, what is involved in good monitoring and how patients are becoming more actively involved in all processes, as it is ultimately about our quality of life.
Table of Contents
Introduction – Who is Prof. Tjalf Ziemssen?
Basics and decision-making
Management of relapses
Generics and their influence on therapy
Monitoring and adjustment of therapy
Patient recommendations and quality of life
Farewell
Introduction – Who is Prof. Tjalf Ziemssen?
Dr. Tjalf Ziemssen is Professor of Clinical Neuroscience and Head of the MS Center Dresden at the University Hospital Carl Gustav Carus. He also initiated and directed the German and international Master’s Program for Multiple Sclerosis Management. He is a health visionary, digital health expert, pioneer of the digital twin and keynote speaker.
Where can people find you and your scientific work on the Internet?
The German video podcasts are on our YouTube page. Otherwise, our German podcasts take place on the first Tuesday of every month. And we hope to have you with us this year. We’re not as productive as you are, because I have to do other things from time to time.
Tjalf Ziemssen on PubMed
---
See you soon and try to make the best out of your life,
Nele
For more information and positive thoughts, subscribe to my newsletter for free.
Click here for an overview of all podcast episodes published so far.
Choosing the right immunotherapy for each individual patient is a complex process. Prof. Ziemssen explains what needs to be considered.
You can read the full transcript of the interview here: https://ms-perspektive.com/58-immunotherapy
Today’s interview on immunotherapy for MS marks the start of the series on disease-modifying therapies. It is also episode 250 for the German podcast and I translated it into English. I have once again invited Prof. Dr. Tjalf Ziemssen, who is one of the most committed MS experts and, among other things, initiated the Multiple Sclerosis Management Master’s program in German and English, which I myself have been attending since August 2022. Thanks to this very well-founded study program, I have gained enough expertise to be able to pass on my knowledge of the therapies to you.
Prof. Ziemssen answers important questions about the procedure, the selection and why it is so important to appreciate it when you see nothing in MS, when you manage to achieve disease remission. We also talk about why it is sometimes more important to move quickly into preventative therapy rather than focusing on rehabilitation and relapse treatment first. A brief detour leads to generics and biosimilars, which are increasingly playing a role in the drug landscape. We talk about how important it is to prevent MS activities as early as possible, what is involved in good monitoring and how patients are becoming more actively involved in all processes, as it is ultimately about our quality of life.
Table of Contents
Introduction – Who is Prof. Tjalf Ziemssen?
Basics and decision-making
Management of relapses
Generics and their influence on therapy
Monitoring and adjustment of therapy
Patient recommendations and quality of life
Farewell
Introduction – Who is Prof. Tjalf Ziemssen?
Dr. Tjalf Ziemssen is Professor of Clinical Neuroscience and Head of the MS Center Dresden at the University Hospital Carl Gustav Carus. He also initiated and directed the German and international Master’s Program for Multiple Sclerosis Management. He is a health visionary, digital health expert, pioneer of the digital twin and keynote speaker.
Where can people find you and your scientific work on the Internet?
The German video podcasts are on our YouTube page. Otherwise, our German podcasts take place on the first Tuesday of every month. And we hope to have you with us this year. We’re not as productive as you are, because I have to do other things from time to time.
Tjalf Ziemssen on PubMed
---
See you soon and try to make the best out of your life,
Nele
For more information and positive thoughts, subscribe to my newsletter for free.
Click here for an overview of all podcast episodes published so far.
58 min